BRADY CORP — Key Metrics

3 years of history · ending 2025-07-31 · SEC EDGAR

Income Statement Cash Flow Balance Sheet Key Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

M-Score (Beneish; >-1.78 flags risk)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Cash-Flow Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)

Book Value Per Share

$25

Free Cash Flow Per Share

Cash Per Share

Revenue Per Share

$31

OCF Per Share

Return on Equity

16.8%

Return on Assets

11.6%

Return on Invested Capital

15.4%

Debt to Equity

0.08

Current Ratio

1.88

Quick Ratio

1.27

Asset Turnover

0.93

Days Sales Outstanding

55.93

Days Payables Outstanding

50.92

Days Inventory On Hand

97.40

Cash Conversion Cycle

102.41

R&D / Revenue

5.3%

SBC / Revenue

0.8%

Capex / Revenue

1.8%

Working Capital

$292M

Net Current Asset Value

$80M

Invested Capital

$1.29B

OCF / Net Income

0.96

FCF / Net Income

0.81

Accruals Ratio (Sloan)

0.5%

Net Debt

$-75M

Net Debt / EBITDA

-0.27

Interest Coverage

49.85

Cash Coverage

38.17

Dividend Coverage

3.98

Capex Coverage

6.57

Tangible Common Equity

$410M

TCE / Total Assets

23.6%

Goodwill / Total Assets

39.0%

NOPAT

$189M

Cash ROIC

12.5%

WC / Revenue

19.3%

Capex / D&A

0.68

Reinvestment Rate

55.6%

Total Payout Ratio

50.9%

Asset Growth vs Revenue Growth

1.6%

Revenue 5Y CAGR

7.0%

EPS 5Y CAGR

11.0%

FCF 5Y CAGR

6.2%

EBITDA 5Y CAGR

11.4%

Book Value 5Y CAGR

9.7%

Stock Price (FY-end)

$70

Market Cap

$3.36B

P/E Ratio

17.77

P/S Ratio

2.22

P/B Ratio

2.82

P/TB Ratio

8.20

P/OCF Ratio

18.56

P/FCF Ratio

21.89

Enterprise Value

$3.29B

EV / EBITDA

11.86

EV / Sales

2.17

EV / FCF

21.40

FCF Yield

4.6%

Dividend Yield

1.4%

Shareholder Yield

2.5%

Buyback Yield

1.5%

R&D Yield

2.4%

Capex Yield

0.8%

Dividend Per Share

DPS YoY Growth

1.9%

Operating Leverage

-0.22

Graham Number

$47

Shares Variation (YoY)

-0.8%

Beta (5Y)

0.71

Cost of Equity

8.1%

Cost of Debt (after tax)

3.8%

WACC

—

ROIC - WACC Spread

—

52W High

$75

52W Low

$63

Trailing Return 1Y

-0.6%

Trailing Return 5Y

63.8%

F-Score (Piotroski)

4.00

M-Score (Beneish)

-2.22

Z-Score (Altman)

6.31

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

BRADY CORP — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation Line	FY2012	FY2013	FY2022	FY2023	FY2024	FY2025
Federal Statutory Rate	35.00%	35.00%	21.00%	21.00%	21.00%	21.00%
State & Local Income Taxes	0.10%	-0.20%	—	—	—	—
Foreign Rate Differential	-6.50%	-2.70%	4.20%	1.70%	0.70%	0.80%
Other Adjustments	-1.00%	-1.00%	-0.40%	-0.30%	-0.10%	0.90%
R&D Tax Credits	-1.00%	3.10%	1.60%	1.30%	1.60%	1.90%
Valuation Allowance Change	—	—	-1.20%	1.20%	0.20%	0.30%
Effective Tax Rate	26.50%	-42.60%	21.90%	22.50%	20.40%	20.20%

Cash vs Accrual

Item	FY2012	FY2013	FY2022	FY2023	FY2024	FY2025
Income Tax Expense (Accrual)	$37.2M	$42.6M	$42.0M	$50.8M	$50.6M	$47.8M
Income Taxes Paid (Cash)	−$35.3M	−$34.0M	$33.8M	$58.8M	$62.1M	$71.1M

BRADY CORP — M&A AcquisitionsNEW

Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.

Gravotech Acquisition

Purchase-Price Allocation

Goodwill

$66.2M

Intangibles

$864.0K

Assets Acquired

$6.8M

Liabilities Assumed

$1.8M

ABR Acquisition